IMPORTANCE Photodynamic therapy (PDT) is an effective and cosmetically favorable treatment modality for actinic keratoses (AKs). However, prolonged incubation times and pain associated with treatment are burdensome to the patient and a hindrance to widespread use of PDT as standard field therapy for AK.
INTERVENTIONS Participants were randomized into 2 incubations arms, either 10-minute or 20-minute aminolevulinic acid (ALA) incubation times, after pretreatment with a microneedle roller (200 um) vs a sham roller. They were blinded to the laterality of microneedle and sham roller assignments. After incubation, they were exposed to blue light (Blu-U, Dusa Pharmaceuticals) for 1000 seconds for a total fluence of 10 J/cm 2 .
MAIN OUTCOMES AND MEASURES
The primary outcome was to quantitatively measure AK resolution, and the secondary outcome was to assess pain associated with microneedle pretreatment.
RESULTS Thirty-three individuals were recruited and randomized to either the 20-minute or the 10-minute incubation arm. Thirty-two participants completed the study with a mean follow-up time of 34.5 days in the 20-minute group, and 30.2 days in the 10-minute group. For the 20-minute incubation arm, average AK clearance was 76% vs 58% on the sham side (P < .01), including 3 patients with complete clearance, although not statistically significant (P = .25) . Pain assessment on the visual analog scale (VAS) during blue light illumination was not significantly different between the microneedle and sham sides (0.7 and 0.4; P = .28), respectively. For the 10-minute incubation arm AK clearance for the microneedle pretreated side was 43% compared with 38% on the sham side (P = .66). Pain during the blue light exposure was not significantly different between the microneedle and sham sides, 4.5 mm and3.4mm(P = .21), respectively.
CONCLUSIONS AND RELEVANCE Photodynamic therapy with microneedle pretreatment at a 20-minute ALA incubation time significantly improved AK clearance with efficacy similar to that of a conventional 1-hour ALA incubation time. The additional advantage to expedited treatment was that the procedure was virtually painless. However, expedited exposure of a 10-minute ALA incubation time did not reach significantly different AK clearance from the sham control.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02594644
A ctinic keratoses (AKs) are considered to be a premalignant manifestation in the continuum of transformation to cutaneous squamous cell carcinoma (SCC). Chronic cumulative sun exposure, fair complexion, immunosuppression, and increased age contribute to increased risk of AK development. The prevalence of AKs in the United States was estimated at 11% to 25% in 2008 with associated annual costs of greater than $1 billion. 1, 2 The risk of progression of AK to SCC is considered low (0.025%-20% per year), but variable, since up to 65% of SCCs are documented to have arisen from lesions previously diagnosed as AKs. 3 Given the high prevalence, economic burden, and possible morbidly and mortality associated with malignant transformation to SCC, standard of care recommendations support treatment for AK on diagnosis. 1 Treatment options for AKs are numerous and depend on several factors, including severity of disease, distribution of lesions, associated costs, and patient preference. While lesiondirected therapy aims to treat clinically identifiable AKs (including cryotherapy, laser therapy, curettage, or dermabrasion), fielddirected therapy aims to also treat subclinical lesions in the surrounding treatment area. Common field therapy options include photodynamic therapy (PDT), topical 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, chemical peels, and ablative laser resurfacing. 2, 4, 5 These treatments show variable long-term efficacy with recurrence in 28% to 96% of patients at the 1-year follow-up, even after complete short-term clearance; therefore, observation and maintenance for AK as a chronic disease are required. 2 The development of new or improved treatment modalities for AKs thus mandates considerations in addition to efficacy, such as duration, convenience, and patient adherence to the treatment. In the United States, the US Food and Drug Administration (FDA) has approved PDT for lesion-directed treatment of minimally to moderately thick AKs of the face or scalp with 14-to 18-hour incubation with 20% topical solution of aminolevulinic acid (ALA) and activation by 10 J/cm 2 of blue light for 1000 seconds. ALA is preferentially absorbed by dysplastic cells and metabolized to protoporphyrin IX (PpIX). When PpIX is activated by a specific wavelength of light in the presence of oxygen, the resultant reactive oxygen species lead to a cytotoxic cascade and destruction of affected cells with minimal damage to surrounding unaffected skin. Cutaneous photosensitivity is transient owing to metabolic conversion of the remaining PpIX to heme within 48 hours. Off-label use of ALA PDT for field therapy with shorter incubation times is common. and several investigator-initiated studies 2,3 have supported efficacy with sustained clearance at a 1-year follow-up time in up to 59% of patients. However, the shallow penetration depth (<2 mm) of ALA, prolonged incubation time, and pain experienced during light exposure are major drawbacks to PDT field treatment. 6 The hydrophilic nature of ALA limits its permeation through the hydrophobic stratum corneum. 7 Innovations for improving ALA penetration or for enhanced conversion to PpIX include incubating ALA under occlusion, methylation of ALA for a more lipophilic substrate, and thermal enhancement of PDT. [8] [9] [10] To specifically address delivery of ALA through the stratum corneum and epidermis, several clinical studies have demonstrated augmentation of PDT by application of metal microneedles to the skin prior to ALA incubation for enhanced mechanical penetration.
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Microneedle rollers are devices that can pierce transient aqueous microchannels in the superficial layers of the skin, thus bypassing the stratum corneum for drug delivery.
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Microneedles have been studied for safety and efficacy in other applications, such as topical anesthetics. 11, 14, 15 They are promising for improving efficacy of PDT because the devices are easy to handle, fast, low cost, and relatively painless, while not increasing erythema, bleeding, or pain during PDT light exposure. 6 In fact, adequate photosensitizer was detected by fluorescence dosimetry in as little as 30 minutes after application of methyl aminolevulinic acid after microneedle pretreatment.
8,16
Our previous investigation 13 demonstrated equivalent efficacy of complete AK clearance on the forehead (71.4% vs 68.3%; P > .05) in expedited microneedle PDT with 20-minute ALA incubation vs the standard 1-hour incubation with sham microneedle pretreatment. The current study aimed to expand on these findings and investigate the efficacy of expedited ALA PDT with microneedle pretreatment at short ALA incubation times in a randomized clinical trial. The primary tested hypothesis was that pretreatment with microneedles can enhance penetration of topical ALA and improve efficacy of PDT for AKs on the face at shorter incubation times of 10 or 20 minutes. The secondary hypothesis was that shorter incubation times are associated with less pain during blue light illumination.
Methods

Study Population
Participants were recruited from the University of CaliforniaDavis Dermatology Clinic. To be included in the study, patients (1) had to be at least 18 years of age, (2) had to have at least 3 distinct grade II AKs on the face, (3) had to have been referred for PDT field therapy by a board-certified dermatologist, and (4) did not meet any of the exclusion criteria. Exclusion criteria consisted of (1) active smoking; (2) photosensitizing condition, such as lupus or porphyria; (3) established allergy to ALA; or (4) nonmelanoma skin cancer on the face documented within the past 6 months.
This study was conducted in accordance with the Declaration of Helsinki principles. All participants gave written informed consent and were compensated. The study was approved by the University of California-Davis institutional review board. The trial protocol is provided in Supplement 1.
Study Design
The Microneedle Photodynamic Therapy II (MNPDT-II) was a randomized, single-blinded, split-face controlled, 2-arm clinical trial comparing the efficacy of AK clearance after microneedle pretreatment. Microneedle rollers were applied to half of each participant's face vs a sham roller on the control side. The 2 arms included a 10-minute and a 20-minute ALA incubation time.
The primary outcome was to quantitatively measure AK resolution with pretreatment and posttreatment AK counts on the microneedle-treated side compared with the sham treatment side of the face. The secondary outcome was to assess the participants' pain during microneedle and sham pretreatment and during blue light illumination by participants' ratings on a visual analog scale (VAS).
Recruitment occurred between March 2015 and May 2016, and follow-up was concluded in June 2016. Using a binary randomization scheme, participants were assigned in a 1:1 ratio to either the 10-minute or the 20-minute incubation time arm. A second binary randomization scheme was used to assign each participant to receive microneedle roller or sham roller administration prior to ALA application on the either the right or the left side of the face. The participants were blinded to the laterality of microneedle vs sham roller assignments ( Figure 1 ).
Treatment Protocol
Each participant's face was cleansed with isopropyl alcohol followed by high-resolution photographic imaging of the face with the Brigh-Tex Bio-Photonics Research 3-D System. Baseline demographic data were collected for each patient. Prior to intervention, each participant was evaluated on clinical examination for extent of disease by a trained blinded investigator (T.A.P. or R.K.S.). Grade II AKs (moderately thick and visible) were mapped on a transparent overlay for both sides of the face (including forehead, nose, upper and lower cutaneous lips, cheeks down to jaw line, and chin). Lip and eyelid keratoses were not included). Transepidermal water loss (TEWL) measurements were recorded with either Tewameter TM 300 (Courage and Khazaka) or Vapometer (Delfin Technologies Ltd) at 4 points of the patients' forehead and cheeks.
According to the binary randomization scheme, each patient had either a microneedle or a sham roller applied to each respective half of the face for a total of 8 forward and backward passes in 4 directions (vertical, horizontal, and each diagonal) . The patients were blinded as to which side of the face would receive the microneedle intervention (Video). The microneedle device (MTS Roller MR2 Clinical Resolution Laboratory Inc) consisted of a single-use sterile array of microneedles 200 μm in length. The sham treatment consisted of the applicator roller without actual microneedles. Immediately after sham and microneedle pretreatment, each participant rated their pain on a 100-mm VAS for each respective side of the face. 17 The TEWL measurements were repeated at the 4 points of the patients' forehead and cheeks. Topical ALA (ALA, Levulan Kerastick, DUSA Pharmaceuticals) was applied to the entire face, and time for incubation was based on the previously determined randomization protocol of either the 10-minute or 20-minute study arm. At the end of the incubation period, participants were exposed to blue light (Blu-U, Dusa Pharmaceuticals) with a mean (SD) wavelength of 417 (5) nm, for 1000 seconds for a total fluence of 10 J/cm 2 .
Immediately after blue light exposure, participants again rated their pain on a 10-cm VAS for each respective side of the face. The participants were instructed to avoid sun exposure for 36 hours after treatment and returned for follow-up approximately 1 month after treatment. At that time their face was photographed, and remaining AKs were counted and mapped. The participants were also asked about any adverse events they may have experienced as result of PDT (eFigure 1 in Supplement 2).
Statistical Analysis
Based on pilot data for the primary outcome, at least 12 patients were required in each group to detect a 25% difference in the clearance of AKs between the split-face treatment groups with 95% power with α = .05. Data are presented as mean ± standard error of the mean. t Test was used to compare the significance between data points. Analysis for complete clearance was calculated with McNemar test for paired proportions. All analyses were conducted using Excel (Microsoft Corp) or GraphPad Software (GraphPad Software Inc). P <.05 was taken to represent a statistically significant difference.
Results
Thirty-three individuals were recruited and randomized to either the 20-minute or the 10-minute incubation arm. One patient in the 20-minute group was excluded from the study after violating protocol and experiencing an adverse event of excessive pain, erythema, and peeling owing to prolonged sun exposure immediately after treatment on the first study visit. Thirty-two participants completed the study with a mean follow-up time of 34.5 days in the 20-minute group, and 30.2 days in the 10-minute group. There were no significant differences in the baseline demographics of age and sex between the 2 study arms ( Table 1) . The mean total grade II AK counts on the face at enrollment were 25 for the 20-minute group and 31 for the 10-minute group. All participants had at least 8 AKs on the face. There were no significant differences in total AKs between the 2 groups, or between the microneedle and the sham side of the face within each group.
Arm 1: 20-Minute Incubation
In the microneedle pretreated side there was an average of 76% AK clearance, compared with 58% on the sham side (P < .01), including 3 patients with complete clearance, although this was not statistically significant (P = .25). TEWL measurement increased on average by 36% for the microneedle side vs 0% for the sham side (P < .001), confirming adequate production of pores through the stratum corneum to facilitate improved drug delivery. One participant was not included in the TEWL final analysis owing to missing data from equipment malfunction. Pain assessment on the 10-point VAS for the microneedlepretreated side averaged 1.3 and statistically different from the sham side of 0.3 (P = .02). However, pain during the blue light exposure was not significantly different between the microneedle and sham side (0.7 and 0.4, respectively; P = .28). See Table 
Arm 2: 10-Minute Incubation
In the microneedle-pretreated side there was an average of 43% AK clearance compared with 38% on the sham side (P = .66), including 1 patient with complete clearance (P > .99), neither significantly different. The TEWL measurement increased on average by 40% for the microneedle side vs 2% for the sham side (P < .001). Pain assessment on the VAS for the microneedlepretreated side averaged 1.4 and was statistically different from the assessment on sham side, 0.3 (P = .004). However, pain during the blue light exposure was not significantly different between the microneedle and sham side, with VAS assessments of 0.5 and 0.3 (P = .21), respectively. See Table 
Discussion
The MNPDT-II trial aimed to evaluate efficacy of AK clearance with microneedle-assisted PDT prior to ultra-short ALA incubation times of 10 and 20 minutes. Participants experienced significantly superior AK lesion clearance (76% vs 58%) at 20-minute incubation times. While the 10-minute group also experienced improvement in AK counts, the clearance rates between the microneedle side and the sham side were not significantly different (43% vs 38%). Interestingly, the secondary outcome of pain associated with blue light exposure during PDT was nominal and not significantly different from the sham side (0.7 vs 0.4 on a 10-point VAS for the 20-minute group). The study confirms and expands on the MNPDT-I pilot study that showed equivalent complete AK clearance rates between 20-minute ALA incubation with microneedle pretreatment vs traditional PDT with 1-hour incubation. Abbreviations: AK, actinic keratoses; ALA, aminolevulinic acid; MN, microneedle; PDT, photodynamic therapy; SEM, standard error of the mean; TEWL, transepidermal water loss; VAS, visual analog scale.
Research Original Investigation Expedited Microneedle-Assisted Photodynamic Therapy for Actinic Keratoses
The AK clearance rate in the MNPDT-II trial is similar to those in previous investigations of traditional PDT with ALA incubation times of 1 hour (78.6%), 2 hours (76.5%), and 3 hours (80.0%) at the 12-week follow up.
2 An even shorter incubation time was investigated under occlusion of an ALA patch for 30 minutes but showed AK clearance rates of only 47% at the 4-week follow up.
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While microneedle pretreatment improved efficacy of PDT at the 20-minute ALA incubation, it did not show significant difference in AK clearance at the 10-minute incubation time compared with the sham control (43% vs 38%). While assisting drug delivery through the stratum corneum and epidermis with microneedles may expedite ALA incubation, it is likely that the additional steps required for downstream conversion of ALA to activated PpIX, production of the resultant reactive oxygen species, and apoptosis require more time. Future studies aimed at expediting the downstream biochemical cascade, such as with thermal PDT, may be warranted to improve efficacy of AK clearance at even shorter ALA incubation times. 19 Interestingly, in both arms of the trial, the sham side of the face had rates of AK clearance (58% for 20-minute ALA incubation and 38% for 10-minute incubation) higher than previously reported vehicle placebo PDT (7.1%).
2 Similarly, in another study, 20 AK clearance after 15 minutes of ALA incubation time but a prolonged PDT light exposure of 1 hour also revealed AK clearance rates of 52%. An additional benefit identified in the MNPDT-II trial is the relatively painless illumination phase (0.7 for the 20-minute group and 0.5 for the 10-minute group on the 10-point VAS) A, In the 20-minute aminolevulinic acid (ALA) incubation arm (n = 16 patients), the microneedle-pretreated side had a mean AK clearance of 76% vs 58% for the sham side (P < .01). In the 10-minute ALA incubation arm (n = 16 patients), the microneedle-pretreated side had a mean AK clearance of 43% vs 38% for the sham side (P = .66). B, In the 20-minute ALA incubation arm (n = 15 patients), the mean change in transepidermal water loss (TEWL) after microneedle pretreatment was 36% vs 0% for the sham side (P < .001).
In the 10-minute ALA incubation arm (n = 16), the mean change in TEWL after microneedle pretreatment was 40% vs 2% for the sham side (P < .001).
Error bars indicate the standard error of the mean; NS, not significant.
a Statistically significant. A, In the 20-minute aminolevulinic acid (ALA) incubation arm (n = 16 patients), the mean pain assessment on the 10-point visual analog scale (VAS) for the microneedle-pretreated side was 1.3 vs 0.3 for the sham side (P = .02). In the 10-minute ALA incubation arm (n = 16 patients), the mean pain assessment on the microneedle-pretreated side was 1.4 vs 0.3 for the sham side (P = .004). B, In the 20-minute ALA incubation arm (n = 16 patients), the mean pain assessment during blue light illumination for the microneedle-pretreated side was 0.7 vs 0.4 for the sham side (P = .28). In the 10-minute ALA incubation arm (n = 16 patients), the mean pain assessment for the microneedle-pretreated side was 0.5 vs 0.3 for the sham side (P = .21). Error bars indicate the standard error of the mean; NS, not significant. compared with reported scores of 4.6 for traditional PDT after 3 hours of ALA incubation. 21 In fact, initial PDT trials of 14-to 18-hour ALA incubation had 90% of patients reporting moderate to severe pain. 22 The rates were reduced for shorter incubation times of 1 to 3 hours, for which 60% of patients reported moderate to severe pain. 20 No participants in the MNPDT-II trial reported moderate or severe pain (6-10 on the VAS). Pain associated with PDT is the most severe adverse effect and may lead to interruption or discontinuation of treatment, resulting in refusal to repeat the process at a future date owing to unbearable discomfort. In addition, most patients reported minimal erythema and peeling and virtually no edema or pain after treatment. Corroborating similar results have been obtained previously where greater incidence of post-PDT severity of erythema and crusting was associated with greater ALA incubation time, but without significant improvement in efficacy of AK clearance.
3
Limitations
A limitation of the current study is the short follow-up time of 4 weeks after treatment. Because actinic damage is cumulative, there is potential for thicker AKs to recur or for new lesions to develop during a longer follow-up period. However, a previous study 3 has reported that prolonged lesion clearance may be achieved by having the patient undergo a second PDT treatment after 8 weeks, with similar efficacy of AK clearance between the 1-hour (68%-79%) and the 18-hour (83.4%) FDA-approved incubation time with the 2-treatment approach. In practice, PDT treatments are typically delivered 2 or 3 times over the period of 2 to 3 months. Future studies should assess AK clearance over a longer period of time, and the results of this pilot study warrant further study of 20-minute incubation PDT, especially after microneedle pretreatment. Another limitation is that our study focused on the face, and further studies are needed before the results reported herein can be extrapolated to the arms.
Conclusions
The results of the MNPDT-II trial support efficacy of microneedle pretreatment for short ALA incubation time of 20 minutes, similar to conventional ALA PDT of 1-hour incubation. In addition, patients felt little to no pain while achieving AK clearance rates of 76%. Limitations of the trial are small number of participants and a short follow-up period. Largescale randomized clinical trials evaluating microneedle augmentation for shorter PDT incubation times are needed to further validate the observed efficacy of treatment and reduction in patient discomfort. Overall, the findings are promising for shortening treatment time and achieving greater patient satisfaction for PDT without compromising efficacy.
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NOTABLE NOTES
The Cutaneous Cancer of Ferdinando Orsini, 5th Duke of Gravina
Raffaele Gaeta, MD; Luca Ventura, MD; Gino Fornaciari, MD
The Abbey of Saint Domenico Maggiore in Naples (14th century) holds 37 wooden sarcophagi of several Aragonese kings, princes, and other nobles (15th-16th centuries). 1 The preserved, natural mummy of Ferdinando Orsini, 5th Duke of Gravina (who died in 1549), which was in good condition, is in one of the arks. The face was completely skeletonized and covered by a veil that hid a widely destructive lesion of the right orbit and of the root of the nose (Figure) . Radiographic examination of the skull confirmed the extensive loss of bone with an osteolytic process involving the entire adjacent bone structures, which appeared rarefied, irregular, and without signs of delimitation. Histological examinations of residual skin fragments at the periphery of the lesion showed clusters of partially necrotic cells in concentric array with solid, epithelial-like aspects and hyperchromatic nuclei. Bone histologic analysis revealed several lacunae destroying the normal lamellar bone. Masses of necrotic epithelial-like cells, similar to those found in surrounding skin, were observed inside one of the largest lacuna. The border between the bone and the underlying neoplastic tissue was sharp, and the brownish, epithelial-like tumor revealed dark margins (looking like a palisade) separated from the bone by clefting spaces. The epithelial origin of the neoplastic cells of the osteolytic tumor was confirmed by the indirect immunofluorescence technique, using the application of monoclonal antiserum directed against pancytokeratine KL1 (Sorin), diluted 1:500. There were intensely positive cell membranes within the cancer.
The positive cytokeratin stain excluded primary bone tumors (classically located in the long bones and rare in adult age), secondary bone tumors (often multiples and located in vertebrae, ribs, and pelvis), and hematopoietic tumors (multiple lesions of the diploe of the skull) from the differential diagnosis. Thus, a diagnosis of skin cancer was considered. Basal cell carcinoma is locally aggressiveness and causes skin ulceration and osteolysis (hence the Latin name of ulcus rodens). It is histologically characterized by a front of neoplastic invasion with cells arranged in palisade and cleft-like artifactual retraction spaces, which divide the tumor from the healthy tissue. In addition, cells are positive for cytokeratin staining.
1) Protocol Title
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
2) Author of Protocol UC Davis Researcher
Researcher from other institution Private Sponsor Cooperative Group Other: _________________
3) IRB Review History
This is a new IRB protocol however it is in follow-up of a previously IRB approved study titled "The Use of Microneedles in Photodynamic Therapy" (IRB# 282150).
4) Objectives
Investigate whether pretreatment with microneedles can decrease the required incubation times of the topical aminoleveulininc acid (ALA) prior to exposure to blue light photodynamic therapy.
5) Background Photodynamic therapy (PDT) is an established treatment for actinic keratoses (AK).
The current standard of care of PDT application at the UC Davis Department of Dermatology, includes pre-treatment of the area with topical aminolevulinic acid (ALA) for 1 hour, followed by treatment with blue light.
Our group conducted a pilot study at UC Davis titled "The Use of Microneedles in Photodynamic Therapy". The global aim of this pilot study was to investigate how microneedles can facilitate the penetration and efficacy of photodynamic therapy, and specifically to investigate whether pretreatment with microneedles enhances penetration of topical aminolevulinic acid (ALA) that is FDA approved and marketed as Levulan® Kerasticks by DUSA Pharmaceuticals, Inc.
This pilot study thus far has demonstrated that microneedles enhance penetration of topical ALA as compared to the control group. More impressively the study has demonstrated that pre-treatment using microneedles with ALA with 20 minute incubation demonstrated equal outcomes as the control group without microneedle treatment and 1 hour incubation.
This demonstration of equal efficacy with decreased incubation time is important as it alleviates one of the major barriers to PDT which is the time needed for administration of this therapy. This is now a follow-up study where we will used reduced incubation times for both the microneedle and sham microneedles treatment sites such that the study will be head to head along incubation times. 
7) Number of Subjects
A total of 30 subjects will be randomized into two treatment groups of 15 subjects each. This number was calculated based on a power analysis that revealed that 12 subjects were needed in each group to have a 95% power to detect a 25% difference in the clearance of actinic keratoses between the split face treatment groups with the at 0.05. Each of the microneedle treatment groups (10 min and 20 min) will consist of split-face comparisons of control topical application of aminolevulinic (sham microneedles). We will recruit 30 subjects to allow for a 20% dropout rate.
8) Recruitment Methods
Potential subjects will be identified from the existing patient base at the UC Davis Department of Dermatology and will be recruited during their clinic visit. In addition, potential subjects that have been evaluated, informed, and referred for photodynamic therapy by a UC Davis dermatologist will be subsequently approached formally to participate in the study prior to their follow up in the photodynamic therapy clinic either by telephone (see script) or in person.
We will indicate that the patients will receive the same options for care regardless of whether they decide to participate or not participate in the study. They will be reassured that their clinical care will be provided to the same level whether they participate or not.
We request a waiver of HIPAA authorization for research for the purposes of screening and recruitment of subjects via electronic medical records.
The size of the potential study population is so large that it would not be practicable to obtain consent.
PROTOCOL TITLE: The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
Revised: September 04, 2013
The screening procedures pose no more than minimal risk to participants (including risks to privacy). The only record linking the participants and the research data would be the consent document, and the main risk of research would be a breach of confidentiality [45 CFR 46. 117 (c) (1)].
All subjects enrolled in the study are assigned a unique subject ID. All PHI recorded will be linked the subject ID only. A key matching each subject with their IDs is kept separate from recorded PHI. All paper study documents are kept in locked cabinets in locked offices only accessible by authorized personnel. Electronic data is password-protected and kept on secure servers.
All PHI will be destroyed at the earliest opportunity consistent with the study.
PHI will not be inappropriately reused or disclosed to any other person or entity other than those approved in this study.
9) Compensation to the Subjects
The subjects will be paid a total of $30 dollars for their participation in the entire study. The subjects will receive $15 for the first day of participation and $15 for their 1 month follow-up visit. Subjects who drop out of the study or are withdrawn will be given a prorated sum.
10) Study Timelines
Subjects will be treated with PDT on day 1 of the study and will be seen for a follow-up visit one month post-treatment. The first study visit may last up to one hour. The subsequent visit will last about 30 minutes.
11) Study Endpoints
The primary endpoint will be the difference in the percentage of complete clearance of the actinic keratoses as an intraindividual comparison between the treatment groups using the paired t-test.
The secondary endpoint will be any pain associated with the microneedle pretreatment and with the application of the PDT.
12) Procedures Involved
After the subject has been consented, the Treatment Visit will commence. Subjects will be randomized into one of two groups. Group 1 will be the 10-minute topical ALA (Levulan® Kerasticks) incubation group. Group 2 will be the 20-minute topical ALA incubation group. All of the subjects will be randomized by binary randomization into each of the treatment groups and then undergo secondary binary randomization for application of the microneedle treatment (vs. sham microneedle treatment) to the right or left side of the entire face.
The subject's face will be cleansed followed by photographic imaging of the face. Next, a Transepidermal Water Loss Meter (Tewameter) will be used to measure the water evaporation gradient on the skin, known as the transepidermal water loss (TEWL). The Tewameter is a non-invasive and painless device that has been widely used for the study of skin barrier function (Figure 3) . Each device has a flat-top electrode (approximate diameter of 1cm) that will come in contact with the skin surface during measurements. The device in held in place for a few seconds while it takes its measurement. This device does not deliver any energy to the skin and works by measuring the density gradient of the water evaporation from the skin indirectly by the two pairs of sensors (temperature and relative humidity) inside the hollow cylinder. This is an open chamber measurement. The open chamber measurement method is the only method to assess the transepidermal waterloss continuously without influencing its micro environment. A microprocessor analyzes the values and expresses the evaporation rate in g/h/m 2 . The subjects will not experience discomfort during and after the measurements. The electrode tip will be cleaned with alcohol wipes before and after use with each subject. Measurements will be made on the right and left forehead and on the right and left cheeks.
Then the face will be subjected to microneedle pretreatment. The microneedle pretreatment will consist of rolling the microneedles or sham microneedles into the skin for several seconds on the sides of the face that have respectively been randomized to the microneedle or control treatment. Sham microneedles will consist of a flat roller without the presence of the microneedles. The microneedles are solid and are long enough to penetrate the stratum corneum and enter the epidermis. Microneedles that are 650 micrometers in length have been shown to induce minimal pain that was rated a 1 out of 10 on a visual analog pain scale (results of IRB# 282150). For this study, subjects will rate pain on a visual analog scale after pretreatment as well.
Then, TEWL measurements will be obtained with the Tewameter again from the right and left face (forehead and cheeks).
Next, topical ALA will be applied. Topical ALA is an FDA-approved product for use in photodynamic therapy. Photodynamic therapy will be done per the usual protocol used at the dermatology clinic.
Follow-up visits will be at one month post-treatment.
During the follow-up visit the patient will be asked about side effects or any adverse events. Imaging will be performed with a non-invasive photographic setup that will be provided by Brigh-Tex Bio-Photonics. To perform the imaging, the study subjects place their face on a chin rest and a series of images are taken of their face that involve blue light and white light (www.btbp.org) similar to how this was used in the previous study (IRB #282150).A sample image from their website is included as figure 
13) Data and Specimen Banking
No tissue will be removed or collected as a part of this investigation.
14) Data Management and Confidentiality
Each of the subjects' signed consents will be filed in a locked cabinet within a locked room. All of the subjects will be entered into the data analysis sheets as codes and a separate password protected file will contain the key for these codes. All of the files will be saved on computers that will be within locked rooms.
15) Provisions to Monitor the Data to Ensure the Safety of Subjects
The subjects will be monitored clinically during the treatment for any evidence of pain or blisters. All of the treatments are done with topical aminolevulinic acid, which has already undergone safety testing and received FDA approval for the treatment of actinic keratoses.
No regular blood draws or labs will be necessary. Because the treatments are all localized topical applications, no systemic effects are anticipated.
However, the subject will be given a contact number on the consent forms in case there are any treatment related adverse effects such as erythema, blisters, pain, or secondary infection and these side effects will be noted in a secure document.
Secondary infections will be treated with appropriate antibiotics and local inflammation will be treated with topical steroids as necessary. 
16) Withdrawal of Subjects
Subjects may be withdrawn by the investigators at any time at their discretion. If a subject chooses to withdraw from this trial at any point, he or she will be treated for actinic keratoses per current standard of care.
17) Risks to Subjects
There is a low chance for any physical, psychological, social or legal injury from the participation. The subject will be warned of the standard risks of treatment with topical aminolevulinic acid including erythema, pain, blisters, increased temporary photosensitivity for 36 hours after treatments, and risk for hyperpigmentation and hypopigmentation.
These reactions will be localized and can be adequately managed and controlled with wound care and topical antibiotics if the subject were to develop a secondary infection at the treatment sites. It is also possible, although unlikely, that the subject may develop contact dermatitis after exposure to the topical aminolevulinic acid. This can be adequately managed with topical steroids and topical antibiotics for any secondary infection.
18) Potential Benefits to Subjects
Each subject involved has potential to derive benefit in this study as they may see regression of their actinic keratoses as part of the study result. Also, the outcome of the research may lead to the development of methods for painless anesthesia that may benefit the subject in the future.
19) Vulnerable Populations
No vulnerable populations will be recruited for this study.
20) Multi-Site Research
This is a single center study.
21) Setting
The study will be performed at the UC Davis Dermatology Clinic (3301 C Street, Sacramento, CA 95816).
22) Resources Available
This is an investigator-initiated study. Funding will be provided through departmental funds.
The Dermatology department and clinic at UC Davis are available for use and that will consist of sufficient personnel to conduct the study. The UC Davis Department of Dermatology has two dedicated clinical research exam rooms and waiting rooms. Therefore that is sufficient personnel and space to conduct the study.
The personnel involved in this study, their qualification and their roles are as follows:
Dermatology 
23) Provisions to Protect the Privacy Interests of Subjects
All of the subject information will be coded to allow for efficient data analysis without using the actual subjects' names or medical record numbers. The data will be input into password protected files that are stored on computers that require password entry. The key for the subject codes will also be saved as a password protected file. Furthermore, the computers will be located within a locked room such that there are three levels of security (one for the password protected file, the second level for the password protected computer, and the third for the locked room). All paper consents will be maintained within a locked cabinet within a locked room.
We plan to eventually publish our data as a clinical report and so we will keep all of the consent files in a locked cabinet and all of the data in a locked room for at least five years. After the five years, we will destroy all of the consents and we will delete the file that contains the key to link the codes to specific subjects.
24) Compensation for Research-Related Injury
25) Economic Burden to Subjects
The subject may incur costs associated with travel to and from the UC Davis Dermatology clinic. The blue light exposure portion of the therapy will not be covered through the research study and this portion may be billed to the subject's insurance. The subject will be made aware of this.
26) Consent Process
We will obtain written informed consent from all subjects. The consent process will take place at the UC Davis Dermatology Clinic. We will follow the Informed Consent Process for Research (HRP-090).
We will not be enrolling children and adults who are cognitively impaired or unable to consent.
27) Process to Document Consent in Writing
We will be following Written Documentation of Consent/Assent (HRP-091).
28) Drugs or Devices
Pre-sterilized microneedles will be used with each subject. The MTS Roller TM MR2 (200 micrometer in length) is available from Clinical Resolution Laboratory, Inc. (product information attached). These microneedles are already approved for use in Europe and are in the process of seeking Class I exemption status from the FDA since they are shorter than existing class I exempt microneedles, such as the microneedles that were used in the previous IRB approved study and were 650 micrometers in length (IRB #282150). We would like to use the microneedles from Clinical Resolution Laboratory, Inc. as they are designed as a roller allowing for greater ease and efficiency with the pre-treatment for both the investigator and the subject. The previous microneedles were used as a stamp method and do not come in a roller design. Because the microneedle roller we would like to use for this study is more than three times shorter than the previously used microneedles, they are safer than the existing class I microneedle (3M Microchannel Skin System). Furthermore, each microneedle roller from Clinical Resolution Laboratory, Inc. is prepacked in sterilized form. Because the handles are made of a plastic polymer base and the needles are made of stainless steel, the microneedle rollers will be sterilized with the liquid chemical sterilization protocol provided as a service to the UC Davis Dermatology Clinic after each use prior to use on the next subject. There are no hollow bores to any of the needles and all needles are solid. The FDA provides guidance in that devices that are minimal risk are at the discretion of the IRB and do not require an IDE. We believe that this is true especially since these microneedles are shorter than microneedles that are already classified as Class I exempt devices. We have attached the information sheets for both the MTS Roller TM CR2 device that we would like to use in this study and the 3M Microchannel Skin System which was used in our previous study.
Transepidermal Water Loss Meter: Measurements will be performed with noninvasive devices that have been widely used for the study of skin barrier function (Figure 3) . Each device has a flat-top electrode (approximate diameter of 1cm) that will come in contact with the skin surface during measurements. The subjects will not experience discomfort during and after the measurements. The electrode tip will be cleaned with alcohol wipes between subjects. (Courage and Khazaka ® , Cologne, 
